Integration and growth strategy
My understanding is that the integration of all the different businesses under the Alcidion umbrella is proceeding well and has exceeded expectations. Feedback from Alcidion is that all employees are embracing the challenge.
Nevertheless, Kate, as CEO, needs to maintain a high level focus and devote efforts to ensure a successful integration. Operational efficiencies need to be identified, and I believe the company is progressing on this front via consolidation of human resource and financial operations.
Alcidion remains committed to pursuing growth via cross-selling opportunities and new markets. As shareholders, we have to back Kate and the previous MKM Health sales and marketing force, given their track record. In terms of new markets, UK remains the option offering the biggest growth potential with opportunities in Wales, Scotland and etc. For North America, Canada is the focus given the similarities of their healthcare system with Australia.
In Asia, Alcidion is still exploring opportunities for partnership. Personally, I do think there is a potential market in Singapore which is attractive given its stable political environment and the nation’s strategic goal of establishing itself as an international medical hub. If possible, I would like to company to continue exploring this option, including establishing contact with private healthcare providers such as the Raffles Medical Group, which has operating medical facilities in thirteen Asian cities. They have the financial firepower, political and business relationships and the creditability.
Domestically, I cannot stress the importance of delivering on the recent ACT contract. Not only is it our biggest contract to date, it is also our first contract for Alcidion integrated product offering. The importance on delivering on what Alcidion promised to deliver and using the ACT as a reference site cannot be overstated.
While it is still fine to use overseas studies to highlight potential benefits and error rates, I think what we really need for wider creditability is results from an Australian hospital – for example, actual cost savings, decline in hospital complications and error rates, productivity and etc. This is what would really help us sell our products and get the market to sit up and notice us.
- Forums
- ASX - By Stock
- Ann: Notice of Annual General Meeting/Proxy Form
Integration and growth strategy My understanding is that the...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALC (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.7¢ |
Change
0.003(4.69%) |
Mkt cap ! $72.51M |
Open | High | Low | Value | Volume |
6.5¢ | 6.8¢ | 6.4¢ | $40.34K | 604.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 6.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 95336 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 256518 | 0.065 |
2 | 539747 | 0.064 |
1 | 200 | 0.063 |
1 | 10000 | 0.062 |
2 | 149000 | 0.061 |
Price($) | Vol. | No. |
---|---|---|
0.066 | 128118 | 1 |
0.068 | 232449 | 1 |
0.069 | 50000 | 1 |
0.070 | 160606 | 2 |
0.071 | 20177 | 1 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
ALC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online